Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synbio Tech's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was NT$67 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$181 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Synbio Tech's annualizedROC % for the quarter that ended in Jun. 2026 was 7.88%.
Synbio Tech's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 11.45%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Synbio Tech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 6.32%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synbio Tech EBIT Related Terms
Synbio Tech EBIT Historical Data
* Premium members only.
The historical data trend for Synbio Tech's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Synbio Tech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synbio Tech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synbio Tech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Synbio Tech's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$181 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synbio Tech (ROCO:1295) has a EBIT of NT$181 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Synbio Tech.
Is Synbio Tech's EBIT too high?
Synbio Tech's current EBIT is NT$181 Mil. Overall, Synbio Tech has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's EBIT compare to VRTX and REGN?
Synbio Tech's EBIT of NT$181 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Synbio Tech. Synbio Tech's current EBIT is NT$181 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Based on GuruFocus' analysis, Synbio Tech (ROCO:1295) is currently considered Possible Value Trap. The stock's GF Value™ is NT$82.69, compared to a current price of NT$45.65 — trading 44.8% below its estimated fair value. The current EBIT is NT$181 Mil. Synbio Tech's overall GF Score™ is 61/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current EBIT is NT$181 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synbio Tech (ROCO:1295) Overvalued in 2026?
Based on GuruFocus' analysis, Synbio Tech stock appears to be undervalued.
The current stock price of NT$45.65 is trading 44.8% below its estimated GF Value™ of NT$82.69.
GuruFocus considers Synbio Tech to be Possible Value Trap.
Key valuation signals for ROCO:1295:
EBIT: NT$181 Mil
GF Value™: NT$82.69 vs. price of NT$45.65 (44.8% below fair value)
No single metric tells the full story. See the ROCO:1295 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
61GF Score
Get the complete analysis for ROCO:1295
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1295 has been successfully added to your 
